Hospital
Kalkaska Memorial Health Center
Kalkaska Memorial Health Center was paid $11.28M by Medicaid between Jan 2018 and Dec 2024, across 188 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoKALKASKA MEMORIAL HEALTH CENTER
KALKASKA, MI 49646
KALKASKA, MI 49646
33aNPI1497751309assigned 06/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.28M
24GClaims355,948
24DCodes billed188
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#61 of 86
Median peer was paid$21.55M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,931 | $963K | |
| 2019 | 45,804 | $1.00M | |
| 2020 | 40,539 | $1.30M | |
| 2021 | 55,148 | $1.91M | |
| 2022 | 60,182 | $2.11M | |
| 2023 | 61,673 | $2.18M | |
| 2024incomplete | 47,671 | $1.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 13,815 | 13,089 | $2.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 6,570 | 6,123 | $1.54M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.2% | 10,166 | 9,724 | $925K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.5% | 5,871 | 5,222 | $730K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 1,726 | 1,651 | $560K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.3% | 7,775 | 7,357 | $489K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 1,928 | 1,889 | $395K |
| A0425 | Ground mileage, per statute mile | 3.5% | 3,562 | 2,832 | $392K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.9% | 11,543 | 4,011 | $323K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.3% | 1,149 | 965 | $255K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 2,269 | 1,642 | $237K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 4,313 | 4,199 | $205K |
176 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 1,595 | $201K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 5,483 | $196K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 4,193 | $165K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.4% | 1,518 | $153K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 1.3% | 718 | $151K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 2,986 | $149K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 2,320 | $143K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 1,460 | $138K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.2% | 4,716 | $134K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,683 | $109K |
| 97162 | <1% | 1,453 | $85K | |
| 80053 | Comprehensive metabolic panel | <1% | 20,625 | $77K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,080 | $76K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,028 | $68K |
| 80061 | Lipid panel | <1% | 6,943 | $66K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,874 | $66K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,048 | $60K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 562 | $59K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 382 | $59K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,737 | $57K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 916 | $51K |
| 73564 | <1% | 1,236 | $40K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,069 | $38K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,068 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,202 | $38K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,208 | $37K |
| 73630 | <1% | 1,682 | $35K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 485 | $35K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,583 | $34K |
| 72110 | <1% | 783 | $29K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 557 | $29K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,126 | $29K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,343 | $25K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,272 | $24K |
| 76830 | Ultrasound, transvaginal | <1% | 311 | $23K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,721 | $21K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,477 | $19K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 115 | $18K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 540 | $18K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,217 | $15K |
| 73130 | <1% | 1,102 | $15K | |
| 73030 | <1% | 702 | $14K | |
| 84439 | <1% | 2,611 | $14K | |
| 73610 | <1% | 886 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,278 | $13K |
| 82728 | <1% | 1,387 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,704 | $11K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 607 | $10K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 272 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 238 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,334 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,388 | $8K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 436 | $8K |
| 97161 | <1% | 190 | $8K | |
| 82607 | <1% | 939 | $8K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 34 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 965 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 57 | $7K |
| 73110 | <1% | 373 | $6K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 55 | $6K |
| 83735 | <1% | 6,469 | $6K | |
| 82570 | <1% | 1,915 | $6K | |
| 82043 | <1% | 1,491 | $5K | |
| 83880 | <1% | 1,438 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 350 | $5K |
| 87186 | <1% | 1,871 | $5K | |
| 85027 | <1% | 1,463 | $5K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $5K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 42 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 132 | $5K |
| 86140 | <1% | 5,788 | $5K | |
| 86900 | <1% | 79 | $4K | |
| 87077 | <1% | 1,976 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 342 | $4K |
| 85610 | <1% | 2,627 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,772 | $4K |
| 81025 | <1% | 3,622 | $4K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $4K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 32 | $3K |
| 81001 | <1% | 9,541 | $3K | |
| 85652 | <1% | 2,259 | $3K | |
| 74022 | <1% | 478 | $3K | |
| 84702 | <1% | 383 | $3K | |
| 83540 | <1% | 669 | $3K | |
| 87634 | <1% | 161 | $2K | |
| 86780 | <1% | 263 | $2K | |
| 97163 | <1% | 39 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 218 | $2K |
| 83550 | <1% | 412 | $2K | |
| 83690 | <1% | 4,037 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 28 | $2K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 63 | $2K |
| 82746 | <1% | 182 | $2K | |
| 72050 | <1% | 26 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 26 | $1K |
| 81003 | <1% | 1,029 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 140 | $1K |
| 72070 | <1% | 18 | $1K | |
| 87081 | <1% | 1,506 | $1K | |
| 87340 | <1% | 231 | $1K | |
| 82248 | <1% | 532 | $964.79 | |
| 87088 | <1% | 350 | $946.17 | |
| 76642 | <1% | 25 | $935.55 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,462 | $926.12 |
| 82150 | <1% | 2,389 | $921.64 | |
| 71271 | <1% | 12 | $850.41 | |
| 80076 | <1% | 449 | $828.40 | |
| 84703 | <1% | 1,149 | $709.89 | |
| 87070 | <1% | 304 | $639.17 | |
| 86850 | <1% | 65 | $625.67 | |
| 93225 | <1% | 12 | $612.85 | |
| 73502 | <1% | 41 | $579.35 | |
| 85730 | <1% | 841 | $513.59 | |
| 85379 | <1% | 1,320 | $469.25 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $438.50 |
| 86038 | <1% | 69 | $411.01 | |
| 74018 | <1% | 27 | $376.64 | |
| 80305 | <1% | 691 | $341.15 | |
| 86803 | <1% | 41 | $337.81 | |
| 87807 | <1% | 326 | $308.08 | |
| 87205 | <1% | 290 | $303.91 | |
| 97802 | <1% | 13 | $260.00 | |
| 84484 | <1% | 4,077 | $235.40 | |
| 87040 | <1% | 1,994 | $229.32 | |
| 83605 | <1% | 5,942 | $214.35 | |
| 87210 | <1% | 62 | $159.09 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $153.24 |
| 86039 | <1% | 27 | $152.63 | |
| 84481 | <1% | 13 | $140.47 | |
| 82077 | <1% | 998 | $135.74 | |
| 82962 | <1% | 1,343 | $113.53 | |
| 80306 | <1% | 696 | $102.11 | |
| 82565 | <1% | 36 | $97.16 | |
| 83655 | <1% | 14 | $89.35 | |
| 84100 | <1% | 41 | $73.04 | |
| 85018 | <1% | 57 | $55.33 | |
| 85014 | <1% | 54 | $50.86 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,135 | $47.75 |
| 86431 | <1% | 14 | $38.52 | |
| 84550 | <1% | 13 | $33.90 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 431 | $28.70 |
| 84156 | <1% | 14 | $27.77 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 150 | $18.00 |
| 83874 | <1% | 360 | $16.24 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,277 | $12.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,713 | $3.15 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,734 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 625 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 739 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,092 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 949 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 4,253 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 118 | $0.00 |
| 86901 | 0% | 79 | $0.00 | |
| 96376 | 0% | 175 | $0.00 | |
| 36000 | 0% | 12 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 26 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 40 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 20 | $0.00 |
| 72040 | 0% | 12 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 60 | $0.00 |
| 12001 | 0% | 13 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,625 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 649 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 207 | $0.00 |
| 90715 | 0% | 137 | $0.00 | |
| 80143 | 0% | 145 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 130 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 37 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 102 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 88 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 53 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 48 | $0.00 |
| 80179 | 0% | 155 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 16 | $0.00 |
| 93226 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAYMOND, ANDREW (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Kalkaska Memorial Health Center | Kalkaska, MI | $3.73M |
| Kalkaska Memorial Health Center | Kalkaska, MI | $2.50M |
| Kalkaska Memorial Health Center | Kalkaska, MI | $1.49M |
| Kalkaska Memorial Health Center | Mancelona, MI | $89K |
| Kalkaska Memorial Health Center | Kalkaska, MI | $25K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.